ANI Pharmaceuticals. has been granted a patent for a method of storing and warming a sterile corticotropin composition. The method involves using a multiple-dose vial with specific temperature controls and a silicone-coated rubber stopper, ensuring the composition maintains its integrity during storage and warming. GlobalData’s report on ANI Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ANI Pharmaceuticals, was a key innovation area identified from patents. ANI Pharmaceuticals's grant share as of June 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Method for storing and warming sterile corticotropin composition
The granted patent US11975047B1 outlines a method for storing and warming a sterile corticotropin composition, specifically designed for use in a clinical setting. The method involves storing the composition in a multiple-dose vial containing 80 USP units/mL of corticotropin, which is maintained at a temperature between 2° to 8° C. The vial features a rubber stopper coated with cross-linked silicones. The warming process entails raising the vial's temperature to a range of 18° to 26° C. The composition is characterized by specific amino acid sequences and must contain minimal vasopressin units, ensuring its purity and efficacy. Additional claims detail the physical state of the composition, which transitions from a solid gel at lower temperatures to a liquid gel at warmer temperatures, and the inclusion of various stabilizing agents such as gelatin and phenol.
Further claims elaborate on the composition's formulation, which may include water for injection, and stipulate that the gelatin used should be pyrogen-free. The patent also specifies the vial's construction, which can be made of borosilicate glass and may feature an aluminum seal and a removable cap. Importantly, the method concludes with the potential application of the corticotropin composition in treating conditions such as multiple sclerosis, gouty arthritis, and psoriasis, among others, following the warming process. This comprehensive approach to the storage and preparation of corticotropin aims to enhance its therapeutic effectiveness while ensuring safety and stability.
To know more about GlobalData’s detailed insights on ANI Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
